Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
KY

NASDAQ · KYTX

Kyverna Therapeutics, Inc.

Healthcare · Biotechnology

$7.64

Down-$0.43 (-5.33%)

Updated Sep 10, 2026, 9:53 AM

SID Score

4.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
364.57M
P/E ratio
-2.27
Dividend yield
0.00%
52-week range
$6.98 – $11.62
Volume
918.29K
Avg. volume
697.76K

Price performance

KYTX price history

1M range · 20 trading sessions · Daily adjusted prices

KYTX closed at $7.64 after 20 trading sessions, down 5.09% for the selected period.

Last close
$7.64
Period change
-5.09%
Period low
$7.64
Period high
$8.95
Daily close
View OHLC price history
KYTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$8.00$8.165$7.595$7.64918.29K
Sep 8, 2026$8.17$8.21$7.97$8.07586.39K
Sep 4, 2026$8.26$8.38$8.20$8.25500.82K
Sep 3, 2026$8.71$8.78$8.28$8.35595.29K
Sep 2, 2026$8.37$8.72$8.24$8.615599.97K
Sep 1, 2026$8.27$8.42$7.6001$8.351.78M
Aug 31, 2026$8.33$8.52$8.14$8.475484.45K
Aug 28, 2026$8.52$8.55$8.31$8.37524.93K
Aug 27, 2026$8.58$8.7867$8.45$8.64432.43K
Aug 26, 2026$8.81$8.8388$8.5043$8.61413.82K
Aug 25, 2026$8.36$8.885$8.265$8.84778.21K
Aug 24, 2026$8.32$8.40$8.00$8.24566.15K
Aug 21, 2026$8.24$8.58$8.19$8.42663.61K
Aug 20, 2026$8.73$8.76$8.11$8.13954.01K
Aug 19, 2026$8.81$9.14$8.64$8.87796.72K
Aug 18, 2026$8.80$8.83$8.3612$8.50851.46K
Aug 17, 2026$8.15$8.985$8.00$8.951.15M
Aug 14, 2026$8.10$8.29$7.80$8.17580K
Aug 13, 2026$8.04$8.225$7.78$8.08739.87K
Aug 12, 2026$7.92$8.6647$7.78$8.051.03M

Latest KYTX news

The latest Smart Investors Daily articles mentioning KYTX.

Stock researchCompany · Overview

KYTX research

Overview

Company profile and research snapshot.

Company profile

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.50
Implied upside
—
Analysts
—
KYTX recent ratings
DateFirmRatingTarget
Jun 3, 2026HC Wainwright & Co.Buy—
May 15, 2026HC Wainwright & Co.Buy—
May 13, 2026JP MorganOverweight—
Apr 23, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences: 2026 Wells Fargo Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Wednesday, September 9th, 2026Time: 4:30 p.m. ET Morgan Stanley 24th Annual Global Healthcare Conf

Benzinga · Aug 11, 2026

Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By